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INTRODUCTION
The lifetime prevalence of kidney stone disease is estimated at 
1% to 15%, with the probability of having a stone varying according to 
age,  gender,  race,  and  geographic  location.  Stone  disease  typically 
affects adult men more commonly than adult women. By a variety of 
indicators, including inpatient admissions, outpatient office visits,  and 
emergency department visits, men are affected two to three times more 
frequently than women (Hiatt et al, 1982 ; Soucie et al, 1994 ; Pearle et 
al, 2005).1 
Most stones become symptomatic when they fall into the ureter 
causing pain or obstruction. 
The  goal  of  management  of  patients  suffering  from  ureteral 
calculi is to achieve complete stone clearance with minimal attendant 
morbidity.  Treatments  for  distal  ureteric  stones  include  watchful 
waiting, ESWL, Ureteroscopy and open ureterolithotomy. Although the 
treatment options available to the urologist  are greater now than they 
have  ever  been,  most  patients  with  ureteral  calculi  do  not  require 
intervention.  Ureteral  calculi  4  mm  or  smaller  will  usually  pass 
spontaneously, although in some cases with discomfort and expense to 
the patient. Ureteral calculi of any size may be associated with renal 
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obstruction, and care must be taken to prevent irreversible damage to the 
kidney, whether the patient selects expectant or active treatment.
Various medications used to enhance the stone passage.  It  had 
been demonstrated that α adrenoreceptors antagonists, given to patients 
suffering from renal colic, due to distal ureterolithiasis, had increased 
the frequency of stone expulsion rate, reduced the time to expulsion and 
reduced  analgesics  consumption.Most  of  the  studies  evaluated  the 
efficacy  of  Tamsulosin,  which  is  a  selective  α  1A  and  α  1D 
adrenoreceptors antagonist. (The lower intramural portion of the ureter, 
where it passes through the detrusor muscle contains mostly α 1D and α 
1A adrenergic receptors)
Only very few studies describe the use of Alfuzosin, which is an α 
adrenergic  receptor  blocker  and not  selective  for  any α  1  adrenergic 
receptor, for expulsion of distal ureteric stones.Alfuzosin is a drug with 
a proven efficacy and considered uroselective with high specificity and 
sensitivity, for the treatment of BPH. 
So, the present study was carried out to evaluate the efficacy of 
Alpha blockers for expulsion of distal ureteral calculus.
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To compare the efficacy of Tamsulosin (Receptor Sub selective 
Alpha  blocker)  with  Alfuzosin  (Receptor  non  Sub  selective  Alpha 
blocker) in the management of distal ureteral calculus.
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AIMS & OBJECTIVES
To evaluate the efficacy of Alpha blockers for expulsion of distal 
ureteric calculus.
To compare the efficacy of Tamsulosin (Receptor Sub Selective 
Alpha  blocker)  with  Alfuzosin  (Receptor  non  Sub  selective  Alpha 
blocker) in the management of distal ureteric calculus.
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REVIEW OF LITERATURE
Historical Overview
Ambroise Paré is credited with the first account of ureteral calculi 
in 1564, as he described “the cruel pain [that] tormented the patient in 
that  place  where  the  stone  lodged.”  Morris  reported  in  1898  that 
“operations on the ureter are an advance of the last few years, but not 
many have been recorded up to the present time” (Ballenger et al, 1933). 
In 1910, Gibson of New York described an incision parallel to and just 
above Poupart's ligament,  wholly extraperitoneal,  by which the lower 
ureter, even  down  to  its  entrance  into  the  bladder,  could  be  readily 
exposed. This safe and comparatively easy approach to the ureter placed 
open ureterolithotomy on sound footing. During the last two decades the 
management of urteric calculus has changed radically; with advent of 
ESWL,  Endourologic  approaches,  PCNL,  laparoscopy,  Medical 
expulsive therapy has made the open surgery for urinary stones obsolete. 
Anatomy of Ureter
The  ureters  are  bilateral  tubular  structures  responsible  for 
transporting  urine  from  the  renal  pelvis  to  the  bladder.  They  are 
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generally 22 to 30 cm in length. The normal ureter is not of uniform 
caliber,  with  three  distinct  narrowings  classically  described:  the 
ureteropelvic  junction,  crossing  of  the  iliac  vessels,  and  the 
ureterovesical  junction.  These  three  sites  of  ureteral  narrowing  are 
clinically  significant  because  they  are  common  locations  for  urinary 
calculi to lodge during passage.. 
Ureteral Segmentation and Nomenclature 
The ureter can be divided into upper, middle, and lower segments. 
The upper ureter extends from the renal pelvis to the upper border of the 
sacrum. The middle ureter comprises the segment from the upper to the 
lower border of the sacrum. The lower (distal or pelvic) ureter extends 
from the lower border of the sacrum to the bladder. 
Ureteral Innervation 
The exact role of the ureteral autonomic input is unclear. Normal 
ureteral peristalsis does not require outside autonomic input but, rather, 
originates and is propagated from intrinsic smooth muscle pacemaker 
sites located in the minor calyces of the renal collecting system. The 
autonomic nervous system may exert some modulating effect  on this 
process, but the exact role is unclear. The ureter receives preganglionic 
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sympathetic  input  from the  10th  thoracic  through  2nd  lumbar  spinal 
segments.  Postganglionic  fibers  arise  from  several  ganglia  in  the 
aorticorenal,  superior,  and  inferior  hypogastric  autonomic  plexuses. 
Parasympathetic input is received from the 2nd through 4th sacral spinal 
segments.
Role of the Nervous system in ureteral function
The ureter is a syncytial type of smooth muscle without discrete 
neuromuscular  junctions (Burnstock,  1970)2. Ureteral  peristalsis  may 
persist  after transplantation (O'Conor and Dawson-Edwards, 1959)3  or 
denervation (Wharton, 1932)4, because spontaneous activity may occur 
in isolated in vitro ureteral  segments  (Finberg and Peart,  1970)5, and 
because  normal  ante  grade  peristalsis  continues  after  reversal  of  a 
segment of ureter in situ (Melick et al, 1961)6, it is apparent that ureteral 
peristalsis can occur without innervations. However, analysis of the data 
in the literature clearly indicates that the nervous system plays at least a 
modulating role in ureteral peristalsis.
Parasympathetic nervous system
Although the role of the parasympathetic nervous system in the 
control  of  ureteral  peristalsis  has  not  been  well  defined,  muscarinic 
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cholinergic receptors have been demonstrated in the ureter (Latifpour et 
al,  1989,  1990)7.The  cholinergic  innervation  is  especially  rich  in  the 
distal and intravesical ureter (Hernández et al, 1993)8 
Cholinergic  agonists,  including ACh,  methacholine  (Mecholyl), 
carbamylcholine (carbachol), and bethanechol (Urecholine), in general 
have been observed to have an excitatory effect on ureteral and renal 
pelvic  function,  that  is,  to  increase  the  frequency  and  force  of 
contractions (Vereecken, 1973 ; Longrigg, 1974 ; Rose and Gillenwater, 
1974 ; Morita et al, 1986, 1987 [260] [259]; Maggi and Giuliani, 1992 ; 
Hernández et al, 1993 ; Prieto et al, 1994)9.
Atropine is a competitive antagonist of the muscarinic effects of 
ACh. Even when atropine has been observed to inhibit ureteral activity, 
its effects are frequently minimal and inconsistent (Ross et al, 1967)10, 
thus  providing little  rationale  for  its  use  in  the  treatment  of  ureteral 
calculus.
Sympathetic Nervous system
The  sympathetic  nervous  system  appears  to  modulate  ureteral 
activity as evidenced by the demonstration of adrenergic receptors in the 
ureter (Latifpour et al,  1989, 1990)7 The ureter contains excitatory α-
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adrenergic and inhibitory β-adrenergic receptors (McLeod et al, 1973 ; 
Rose  and  Gillenwater,  1974  ;  Weiss  et  al,  1978)10 that  have  been 
demonstrated with receptor-binding techniques (Latifpour et al,  1989, 
1990)7..  Agents that primarily activate α-adrenergic receptors,  such as 
norepinephrine and phenylephrine, tend to stimulate ureteral and renal 
pelvic activity (McLeod et al, 1973 ; Hernández et al, 1992 ; Rivera et 
al,  1992 ;)7, and  agents that primarily activate β-adrenergic receptors, 
such as isoproterenol and orciprenaline, tend to inhibit ureteral and renal 
pelvic activity (Finberg and Peart, 1970 ; Rose and Gillenwater, 1974 ; 
Weiss et al, 1978 ; Hernández et al, 1992 ;)7 
The human ureter contains α-adrenergic receptors along its entire 
length, with the highest concentration in the distal ureter 11,12 Stimulation 
of  the α receptors  increases  the force of  ureteral  contraction and the 
frequency of ureteral peristalsis,  whereas antagonism of the receptors 
has the opposite  effects.  Malin and colleagues  first  demonstrated  the 
presence  of  α-adrenergic  receptors  in  the  human  ureter  in 
1970.Adenergic receptors along the entire length of the ureter, increased 
tone and frequency of contractions occurs in the ureter when exposed to 
α-adrenergic agonists11
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More  recently,  Sigala  and  colleagues12studied  α1-adrenergic 
receptor gene and protein expression in the proximal, middle, and distal 
ureter. They demonstrated that the distal ureter expressed the greatest 
quantity of α1 messenger ribonucleic acid (mRNA). The α1d mRNA was 
expressed  in  all  portions  of  the  ureter,  and  it  was  expressed  in 
significantly greater amounts than the α1a or α1b receptor subtype in 
both the proximal and distal ureter. Using ligand binding, they were 
able to show that the distal ureter had the highest density of α receptors, 
and α1d was the most  common receptor present in all  portions of the 
ureter
14
α1d > α1b > α1a
α1d > α1a > α1b
α1d > α1a > α1b
There are a number of second messenger intracellular molecules 
that play a role in the contraction as well as the relaxation of smooth 
muscle. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate  (cGMP)  modulate  relaxation,  whereas  inositol  1,4,5-
triphosphate (IP3) and diacylglycerol (DG) are involved in contraction. 
Relaxation occurs after efflux of calcium from the cell and redistribution 
of  this  cation  within  intracellular  organelles.  The  autonomic  nervous 
system  is  involved  in  modulation  of  these  events.  Parasympathetic 
activity  promotes  contraction,  whereas  sympathetic  influences  are 
divergent: α (contraction) and ß (relaxation). 
Ureteral Calculi 
The factors that the urologist must consider when recommending 
treatment  to  patients  with ureteral  calculi  may be grouped into three 
broad categories: stone-related factors, clinical factors, and technical 
factors (equipment available for treatment, costs). These factors may 
be thought of as treatment modifiers; the presence or absence of one or 
more of these factors may shift the balance toward a certain treatment 
modality.
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Factors Affecting Management of Ureteral Stones 
Stone Factors Clinical Factors Technical Factors
Location Symptom severity Available equipment
Size Patient's expectations
Composition Associated infection
Degree of obstruction Solitary kidney
Abnormal ureteral anatomy
Cost
Natural History 
The  indications  for  intervention in  the management  of  patients 
with  ureteral  calculi  have  clearly  been  affected  by  the  increased 
efficiency  and  lower  morbidity  of  minimally  invasive  treatment 
modalities.  Although  the  traditional  indications  for  intervention 
(intolerable or intractable symptoms, infection, obstruction, and a stone 
that is unlikely to pass spontaneously) have not changed, the array of 
technologies currently available allows almost any symptomatic patient 
to be considered a candidate for stone removal. Many patients will pass 
the stone  spontaneously.  A thorough knowledge,  then,  of  the natural 
history of  ureteral  stones  permits  a  well-informed judgment  of  when 
conservative measures (e.g., observation), rather than intervention, are 
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indicated. Furthermore, such data help the patient consider the spectrum 
of options and decide whether to try to endure further symptoms or to 
elect immediate stone removal.
In  the  absence  of  external  ureteral  compression  or  internal 
narrowing,  the width of the stone is the most significant measurement 
affecting the likelihood of stone passage (Ueno et al, 1977)13. However, 
the  measurement  of  stone  size  from  a  plain  radiograph  can  be 
misleading.  Otnes  and  Sandnes  (1978)14  reported  that  stone  size  was 
overestimated  in  59%  of  cases,  was  underestimated  in  15%,  and 
correlated  accurately  with  the  actual  size  in  only  26%.  Ueno  and 
colleagues (1977)13 reported that in a series of 520 patients with ureteral 
stones, those with stones smaller than 4 mm, 4 to 6 mm, and larger 
than 6 mm experienced rates of spontaneous passage of 80%, 59%, 
and 21%, respectively. Morse and Resnick (1991)15  showed that  the 
rate of spontaneous passage is highly dependent on stone location; 
passage  rates  from the  proximal,  middle,  and  distal  ureter  were 
22%, 46%, and 71%, respectively. Hubner and associates (1993)16 also 
reported that the likelihood of spontaneous stone passage was directly 
related to stone size and location at the time of presentation. The rate of 
spontaneous passage for stones smaller than 4 mm was 38% compared 
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with 1.2% for those larger than 6 mm, irrespective of their position in 
the ureter at the time of presentation. Calculi discovered in the distal 
third  of  the  ureter  had  a  spontaneous  passage  rate  of  45%, 
compared with 22% for the middle third and 12% for the proximal 
third. Two thirds of all stones that passed did so within 4 weeks after 
the onset of symptoms. Segura and associates (1997)17 reported in  the 
AUA guidelines on the management of patients with ureteral calculi 
that for stones smaller than 5 mm, the spontaneous passage rate in 
the distal ureter and proximal ureter ranged from 71% to 98% and 
from 29% to 98%, respectively, whereas stones larger than 5 mm 
had a lower spontaneous passage rate, ranging from 10% to 53% 
and  25%  to  53%  for  proximal  and  distal  ureteral  calculi, 
respectively. These rates have been affirmed by a more recent review of 
CT  imaging  of  ureteral  calculi  (Coll  et  al,  2002)18. Therefore,  for 
patients  with  stones  of  5  mm  or  less,  conservative  management 
should be considered, whereas the chance of spontaneous passage for 
larger stones diminishes considerably, and intervention should be more 
readily contemplated.
Miller  and  Kane  (1999)19 analyzed  75  patients  with  ureteral 
calculi and found that the interval to stone passage was highly variable 
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and dependent on stone size, location, and side: for 95% of stones to 
pass, 31 days were required for stones 2 mm or less, and about 40 days 
were required for stones 2 to 6 mm. Furthermore, only 4.8% of patients 
with  stones  smaller  than  2  mm required  intervention  compared  with 
50% of  patients  with  stones  4  to  6  mm.  Cummings  and  coworkers 
(2000)20 trained  an  artificial  neural  network  to  predict  outcome  in 
patients  with  ureteral  stones  with  76%  accuracy.  The  duration  of 
symptoms  before  initial  presentation  was  the  most  influential  factor, 
followed  by  degree  of  hydronephrosis.  The  importance  of  symptom 
duration was reported by several other authors, who concluded that if 
significant  progress  has  not  occurred  after  1  month  of  observation, 
intervention  is  usually  required  (Ibrahim et  al,  1991  ;  Hubner  et  al, 
1993 ; Singal and Denstedt, 1997)21
Factors Affecting Treatment Decisions 
Stone Factors      
Location 
The location at which the passage of a ureteral stone is arrested is 
an important factor in assessing the likelihood of spontaneous passage 
as well as in determining the optimal treatment options and their relative 
successes.  The  statistical  probability  of  spontaneous ureteral  stone 
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passage  is  directly  related  to  the  distance  of  the  ureter  to  be 
traversed and inversely related to stone size. Anatomic location has 
an important effect on what treatment modality has a higher stone-free 
rate. In the 1980s, proximal ureteral stones were commonly treated with 
SWL,  whereas  distal  ureteral  stones  were  treated  with  ureteroscopy 
(Sosa et al, 1987)22 
Stone Burden 
The stone burden, in terms of both size and number, may affect 
what form of therapy will be the most efficient and confer the highest 
stone-free  rate.  The  majority  of  ureteral  stones  pass  spontaneously, 
especially stones less than 5 mm in diameter, and thus can be treated 
with expectant management (Kinder et al, 1987 ; Segura et al, 1997)23 
Stones larger than 8 mm, however, are unlikely to pass spontaneously in 
a  timely  fashion  without  causing  significant  symptoms  and  possible 
renal damage from obstruction (Ueno et al, 1977)13. 
Composition 
Stone composition, if it is known, is useful information to help 
discern which treatment strategy may be favored (e.g., SWL for fragile 
calcium  oxalate  dihydrate  stones  or  ureteroscopy  and  intracorporeal 
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lithotripsy for cystine or brushite stones that are relatively resistant to 
SWL).
Duration of Presence 
The management of patients with ureteral stones may be affected 
by the duration of  a stone's  presence or  the patient's  symptoms.  The 
length of time a stone has been in the ureter is significant because of the 
potential  for  irreversible  loss  of  renal  function.  However,  even  with 
complete ureteral obstruction, irreversible loss of renal function does not 
occur before 2 weeks, although it can progress to total renal unit loss at 
up to 6 weeks (Vaughan and Gillenwater, 1971)24  Because the patient's 
symptoms  and  stone  size  do  not  predict  loss  of  renal  function,  and 
because  there  is  no  clear  time  threshold  for  irreversible  damage, 
intervention  should  be  considered  in  any  patient  with  ureteral 
obstruction  unless  the  ability  to  closely  monitor  renal  function  is 
available. 
CLINICAL FACTORS 
Pain 
Pain (renal or ureteral colic) is the primary presenting symptom of 
most patients with ureteral obstruction and is the source of considerable 
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morbidity.).  Management  of  ureteral  obstruction  on  the  basis  of 
symptoms should be tailored to the amount of time the symptoms have 
persisted. Patients presenting with early symptoms of renal colic may be 
managed expectantly for stone passage as long as their symptoms are 
controllable  with  oral  medical  therapy.  Patients  with  symptoms  of 
longer duration may be more appropriately managed by relieving the 
ureteral obstruction through either the placement of a ureteral stent or 
definitive stone treatment. Patients with ureteral stones causing severe 
symptoms  refractory  to  conservative  and  medical  therapy  require 
prompt treatment.
Infection 
Infection  associated  with  ureteral  stones,  or  obstructed 
pyelonephritis,  is  a  not  uncommon  and  potentially life-threatening 
urologic emergency. Such patients are typically febrile and may present 
with signs of septic shock, such as hypotension. Urgent drainage of the 
obstructed  portion  of  the  urinary  tract  by  either  ureteral  catheter  or 
percutaneous nephrostomy is essential. 
Patient's Expectations 
The patient's expectations must be considered in recommending 
different treatment modalities. For ureteral stones with low probability 
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of spontaneous passage, the patient must be informed of the available 
treatments, including the relative benefits and risks associated with each. 
Solitary Kidney 
Patients with ureteral stones in either surgically or functionally 
solitary kidneys require a modification of standard treatment algorithms. 
A  ureteral  stone  obstructing  a  solitary  kidney  demands  prompt 
attention, usually with internal drainage and definitive stone treatment 
(ESWL or ureteroscopy).
Aberrant Anatomy 
Ureteral  stones  in  patients  with  abnormal  anatomy  (ureteral 
ectopia, ureteroceles, megaureters) may have impaired egress because of 
obstructive or functional factors (Kajikawa et al, 1985 ; Diamond et al, 
1994 ; Dretler, 1995)25 These patients may not respond to therapies such 
as SWL with the same level of success as do those with normal ureteral 
anatomy.  The  anatomic  abnormality  may  need  to  be  corrected  or 
circumvented  to  permit  successful  treatment  of  ureteral  stones.  For 
example, patients with recurrent stones that become lodged and obstruct 
the ureter in a ureterocele should have the ureterocele treated (by either 
23
endoscopic  incision  or  open  excision  with  reimplantation) 
simultaneously with ureteral stone removal.
Technical Factors 
The  treatment  of  patients  with  ureteral  calculi  depends  on 
multiple surgical technologies, and the availability of certain equipment 
will affect the possible options for treatment. tree model to identify the 
most  cost-effective treatment option for patients with ureteral calculi. 
On  the  basis  of  a  comprehensive  literature  review  to  determine  the 
average success rate of observation, SWL, and ureteroscopy, they found 
that  ureteroscopy  is  the  most  cost-effective  treatment  strategy  for 
ureteral stones at all locations, after observation fails. 
Distal Ureteral Calculus
Treatments for distal ureteric calculus include watchful waiting, 
Extracorporeal  shock  wave  lithotripsy,  Ureteroscopy  and  open 
ureterolithotomy. If possible,wathful waiting may be considered as the 
first choice of the treatment because it non invasive and low cost.  The 
optimal therapy for patients requiring removal of distal ureteral calculi 
is  controversial.  SWL and ureteroscopy are  both effective  treatments 
associated with high success rates and limited morbidity. A 1997 meta-
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analysis  performed  by  the  AUA Ureteral  Stones  Clinical  Guidelines 
Panel  established  that  both  ureteroscopy  and  SWL  are  acceptable 
treatment  options  for  patients  with  distal  ureteral  stones.  Both 
recommended  treatment  options,  SWL  and  ureteroscopy,  have  valid 
advantages  and  disadvantages.  The  primary  goal  in  treating  patients 
with ureteral calculi is a stone-free state, and the AUA guidelines panel's 
meta-analytic  study  reported  that  85% of  9422  patients  subjected  to 
SWL were rendered stone free  compared with 89% of 3978 patients 
undergoing ureteroscopy. There have been two randomized prospective 
studies comparing ureteroscopy and SWL for treatment of patients with 
distal  ureteral  stones  subsequent  to  the  guidelines  document.  Peschel 
and  associates  (1999)26  randomized  80  patients  and  found  that  those 
undergoing  ureteroscopy  achieved  stone-free  status  more  rapidly, 
regardless of initial stone size, than did those treated by SWL. All of the 
patients  undergoing  ureteroscopy  were  rendered  stone  free,  whereas 
10% of the SWL cohort required subsequent ureteroscopy to achieve a 
stone-free status. 
There  is  no  validated  instrument  available  to  assess  the 
satisfaction of patients for either of these procedures, although this is an 
important  concern.  Peschel  and  associates  (1999)  measured  patients' 
25
satisfaction  after  ureteroscopy  or  SWL.  They  found that  for  patients 
with stones  smaller  than  5 mm,  all  patients  undergoing ureteroscopy 
reported complete satisfaction, compared with 75% of those undergoing 
SWL. For those with stones larger than 5 mm, all patients undergoing 
ureteroscopy were satisfied,  compared with 95% of those undergoing 
SWL. Pearle and associates (2001)27 also measured patients' satisfaction 
and  found  no  significant  difference  between  SWL  (96%)  and 
ureteroscopy  (89%).  Neither  of  these  studies  used  a  validated 
questionnaire,  and  the  divergent  conclusions  of  these  two  analyses 
emphasize the need for the development of such a device.
Medical Expulsive Therapy (MET) :
MET has been aimed at modifiable factors that can affect stone 
passage.These  factors  are  mucosal  edema,  inflammation, infection, 
ureteral spasm. Several agents have been studied as potential MET.
Calcium Channel Blockers :
Ureteral smooth muscle  contraction is dependent on transcellular  and 
intracellular  calcium  fluxes.  Calculi  may  induce  ureteral  spasm  that 
inhibits stone passage. An effective pharmacologic agent would inhibit 
spasm without  significantly  impacting  ureteral  peristalsis  because  the 
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latter is thought to promote stone passage. Calcium channel blockers, 
which inhibit the influx of extracellular calcium, have been prescribed to 
facilitate stone passage. Nifedipine, verapamil, and diltiazem have been 
shown to inhibit ureteral contraction in guinea pigs and humans.28,29,30,31 
Studies  suggest  that  a  combination  of  nifedipine  and 
corticosteroid therapy is effective in facilitating stone passage. Borghi 
and  associates,  in  a  randomized  double-blind  controlled  trial  of  86 
patients with ureteral stones less than 15 mm in width, demonstrated a 
statistically significant increased stone expulsion rate for patients given 
40 mg nifedipine and 16 mg methylprednisolone daily for a maximum 
of  45  days  than  for  patients  receiving  placebo  and  16  mg 
methylprednisolone  daily  (86% vs  65%).  Furthermore,  mean  time  to 
passage was also statistically significantly less with this regimen than 
with placebo (11.2 days vs 16.5 days)..  Most  recently,  Porpiglia  and 
colleagues, in a randomized prospective trial, demonstrated the efficacy 
of nifedipine and deflazacort (an oral steroid) in treating distal ureteral 
stones ≤ 10 mm in length. The spontaneous passage rate for the control 
arm (75 mg diclofenac as needed) was statistically significantly lower, 
35%, as compared to 79% for the treatment group (30 mg deflazacort 
daily for up to 10 days, 30 mg nifedipine daily for up to 4 weeks, 75 mg 
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diclofenac  as  needed).  Mean  time  to  expulsion  was  also  statistically 
significantly decreased with the treatment arm (7 days vs 20 days) as 
was average amount of diclofenac used (15 mg vs 105 mg). Serious side 
effects  were  minimal,  but  included  transient  hypotension  and 
palpitations.34 
α-Adrenergic Blockers :
Stimulation  of  α-1  adrenergic  receptors  enhances  contractile 
frequency and amplitude. A pharmacologic agent that antagonizes the 
α-1  receptor  activity  should  therefore  decrease  contractile  activity 
associated  with  ureteral  spasm  induced  by  calculi,  thus  facilitating 
passage. There have been reports indicating that the administration of 
selective  α-1  blocking  agents  facilitates  passage  of  ureteral  calculi. 
Cervenakov and associates, in a nonrandomized study, administered 0.4 
mg of tamsulosin, a selective α-1 antagonist, per day to 51 patients with 
ureteral calculi (mean W 4.0 mm and mean L 7.6 mm) and compared 
them to a similar number of patients with ureteral stones of similar size 
(mean W 3.8 mm and mean L 7.5 mm) receiving standard supportive 
care.  Forty-one  of  the  51  (80.4%)  receiving  tamsulosin  passed  their 
stones spontaneously as compared to 32 (62.8%) in the other cohort. 
Time to passage was also more expeditious in the tamsulosin group.37  
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A  recent  randomized  controlled  trial  by  Dellabella  and  associates 
demonstrated that tamsulosin may be effective in facilitating the passage 
of distal ureteral calculi. The patients in this study had calculi ranging 
from 3.8 mm to 13 mm in width. Patients in the treatment group were 
given  oral  floroglucinetrimetossibenzene  3  times  daily  for  up  to  4 
weeks, 30 mg deflazacort daily for 10 days, co-trimoxazole twice daily 
for 8 days, and 75 mg diclofenac intramuscularly as needed, while the 
treatment group received 0.4 mg tamsulosin daily for up to 4 weeks with 
the  same  dosages  of  deflazacort,  co-trimoxazole,  and  diclofenac. 
Passage  rates  were  70%  for  the  placebo  group  and  100%  for  the 
treatment group. Furthermore, mean hours to expulsion (111.1 vs 65.7), 
mean  number  of  analgesic  injections  (2.83  vs  0.13),  number  of 
hospitalizations (10 vs 0), and number of stones requiring ureteroscopic 
intervention (9 vs 0) were all statistically significantly decreased in the 
treatment group. No drug-related side effects were noted in any of the 
60  patients  included  in  the  trial.38 More  recently,  Dellabella  and 
associates showed, in another randomized controlled trial, that treatment 
of patients with distal ureteral calculi with tamsulosin was superior to 
both  placebo  and  nifedipine.  All  enrolled  subjects  received  30  mg 
deflazacort daily for 10 days, co-trimoxazole twice daily for 8 days, and 
75 mg diclofenac intramuscularly as needed. The control group received 
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floroglucinetrimetossibenzene  tablets 3 times  daily,  and the treatment 
groups received either tamsulosin 0.4 mg daily or 30 mg slow-release 
nifedipine daily. The group treated with tamsulosin experienced a more 
statistically significant increase in passage rates than both the control 
and  nifedipine  groups  (97.1%  vs  65.7%  and  75.6%,  respectively). 
Furthermore, a statistically significant decrease in time to passage, lower 
analgesic  requirement,  decrease  in  work  days  lost,  and  decrease  in 
hospitalization  and  need  for  endoscopic  stone  removal  were  also 
demonstrated for the group treated with tamsulosin.39 Terazosin, another 
selective  α-1  adrenergic  antagonist,  has  also  recently  been  shown to 
facilitate  stone  passage.  Tekin  and  colleagues,  in  a  prospective 
randomized trial of 75 patients with distal ureteral calculi ≤ 15 mm in 
width, found that patients treated with 5 mg terazosin daily for 4 weeks 
had a more statistically significant increase in stone passage rate than 
those  patients  receiving no treatment  (77% vs  46%).  Treatment  with 
terazosin was particularly effective for stones < 8 mm, as a statistically 
significant increase in passage rate was noticed for this subgroup (95% 
vs 56%). Drug-related side effects were minimal and no patient dropped 
out of the study.40 
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Tamsulosin  : Tamsulosin  hydrochloride  is  an  antagonist  of 
alpha1  A  adrenoceptors.  Tamsulosin  is  a  once-daily  administered  α1 
antagonist that exhibits some modest degree of selectivity for the α1a 
versus  the  α1b AR and no selectivity  for  the  α1a versus  the α1d AR 
(Foglar  et  al,  1995).  Available  in  0.4  mg,  0.8  mg  forms. It  is 
administered after  a meal,  once daily dose.  The pharmacokinetic  and 
pharmacodynamic  interactions  between  Tamsulosin  and  other  alpha-
adrenergic  blocking  agents  have  not  been  determined.  However, 
interactions  may  be  expected  and  Tamsulosin  should  not  be  used  in 
combination with other  alpha-adrenergic blocking agents.  Tamsulosin 
should be used with caution in combination with cimetidine and with 
moderate or strong inhibitors of CYP2D6 (e.g., fluoxetine) or CYP3A4 
(e.g., ketoconazole), particularly at doses higher than 0.4 mg. 
Adverse  events  were  generally  mild  and  included  dizziness, 
rhinitis, and abnormal ejaculation. These increased in a dose-dependent 
manner  (increased  with  0.8-mg/day  dosage  than  in  0.4  mg/day). 
Tamsulosin is contraindicated in patients known to be hypersensitive to 
tamsulosin  hydrochloride. Tamsulosin  is  not  indicated  in  Pregnant, 
Lactating women, and also in children.
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Alfuzosin: Alfuzosin  hydro  chloride  is  another  α-adrenergic 
blocking  agent  that  has  been  extensively  utilized  in  BPH 
pharmacotherapy.  Alfuzosin  exhibits  no  pharmacologic  uroselectivity 
for any of the α1 subtypes (Andersson et al, 1997). alfuzosin should be 
taken  immediately  following  a  meal.  Available  in  10  mg Alfuzosin 
should  not  be  used  in  patients  with  moderate  or  severe  hepatic 
insufficiency,  since  alfuzosin  blood  levels  are  increased  in  these 
patients. 
Alfuzosin should  not  be  co-administered  with  potent  CYP3A4 
inhibitors  such  as  ketoconazole,  itraconazole,  and  ritonavir,  since 
alfuzosin  blood  levels  are  increased..  Alfuzosin contraindicated  in 
patients  known  to  be  hypersensitive  to  Alfuzosin  hydrochloride. 
Tamsulosin is not indicated in Pregnant, Lactating women,and also in 
children.
Nonsteroidal Anti-Inflammatory Drugs :
In  vitro  studies  of  the  human  ureter  have  demonstrated  that 
prostaglandins  increase  ureteral  smooth  muscle  contractility.41,42 
Nonsteroidal  anti-inflammatory  drug  (NSAID)  agents  that  inhibit 
cyclooxygenase (COX), an enzyme involved in prostaglandin synthesis 
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from fatty  acids,  have  been  used  extensively  in  the  management  of 
patients  with  renal  colic.  Their  benefits  are  based  on  various 
mechanisms including a reduction in RBF that decreases pressure in the 
collecting system, ureteral smooth muscle relaxation, and a decrease in 
stone-induced ureteral edema. The latter 2 effects of NSAIDs have been 
hypothesized  to  facilitate  stone  passage  as  well.  Two  randomized 
controlled trials have assessed the ability of NSAIDs to facilitate stone 
passage.  Kapoor  and  colleagues  demonstrated  that  patients  receiving 
indomethacin  suppositories  (a  nonselective  COX  inhibitor)  did  not 
experience increased stone passage rates or decreased time to passage 
when  compared  to  patients  receiving  placebo.  However,  the  patients 
receiving indomethacin did require a statistically significantly decreased 
amount of narcotic analgesics.43 Laerum and associates showed that oral 
diclofenac,  a  nonselective  COX  inhibitor,  did  not  increase  stone 
expulsion rate compared to placebo. However, diclofenac significantly 
decreased pain and hospital admissions.44
Progesterone :
The  increased  prevalence  of  hydro-ureteronephrosis  beginning 
during  the  second  trimester  of  gestation  and ending  within  1  month 
postpartum  suggests  that  progesterone  and/or  estrogen  may  affect 
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ureteral  function.  It  has  been  proposed  that  progesterone  promotes 
ureteral  dilatation  during  pregnancy  and  delays  the  rate  of  its 
disappearance postpartum. Mikkelsen and colleages treated 24 patients 
of  both  genders  with  a  250  mg  intramuscular  dose  of 
hydroxyprogesterone  to  see  if  this  would  facilitate  stone  passage. 
Fourteen patients (59%) passed calculi while all other patients required 
surgical  removal.45 However,  the efficacy of  this approach cannot be 
determined as there was no control group.
Future Direction of Pharmacotherapy
COX-2 Inhibitors :
The  aforementioned  studies  suggest  that  nonselective  COX 
inhibitors  are  not  effective  in  facilitating  stone  passage.  However, 
COX-2 inhibitors  have  not  been  assessed  in  this  setting.  These  may 
prove  to  be  effective  agents  to  facilitate  stone  passage.  Nakada  and 
associates  have  found  that  the  COX-2  protein  and  its  mRNA  are 
expressed to a greater degree in obstructed human ureter as compared to 
normal  human  ureter.46 Furthermore,  this  group  demonstrated  that  a 
selective COX-2 inhibitor reduced the contractility of both human and 
swine ureter.46,47 
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       Phosphodiesterase Inhibitors :    
The  second  messengers,  cAMP  and  cGMP,  are  mediators  of 
smooth muscle relaxation. cAMP and cGMP breakdown occurs via the 
activity  of  a  family  of  isoenzymes known as the phosphodiesterases. 
Phosphodiesterase (PDE) inhibitors are a class of drugs that inhibit the 
breakdown of cAMP and cGMP, enhancing smooth muscle relaxation. 
Therefore, PDE inhibitors may be able to decrease ureteral spasm and 
facilitate stone passage.49 Taher and colleagues identified the isoenzyme 
PDE IV as being dominant over other PDEs in regulation of ureteral 
smooth  muscle.50  Rolipram,  a  selective  PDE  IV  inhibitor,  has  been 
shown to facilitate ureteral relaxation. Kühn and associates assessed the 
ability of sodium nitroprusside and various PDE inhibitors to promote 
relaxation  of  explanted  human  ureter.  They  found  that  sodium 
nitroprusside and rolipram were the most effective in promoting ureteral 
relaxation of the agents tested. Most recently, Romics and colleagues, in 
a randomized doubleblinded controlled trial, showed that drotaverine, a 
selective PDE IV inhibitor, significantly reduced acute renal colic when 
compared  to  placebo.52 Although  no  studies  have  evaluated  PDE 
35
inhibitors  as  agents  to  facilitate  stone  passage,  the  aforementioned 
properties suggest that this should be investigated.
 
Various clinical trials MET
AUA Guidelines regarding management of distal urteric calculus :
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The  index  patient  is  a  nonpregnant  adult  with  a  unilateral 
noncystine/nonuric acid radiopaque ureteral stone without renal calculi 
requiring  therapy  whose  contralateral  kidney  functions  normally  and 
whose medical condition, body habitus, and anatomy allow any one of 
the treatment options to be undertaken.
Treatment Guidelines for the Index Patient
For Ureteral Stones <10 mm
Option: In a patient who has a newly diagnosed ureteral stone <10 
mm  and  whose  symptoms  are  controlled,  observation  with  periodic 
evaluation  is  an  option  for  initial  treatment.  Such  patients  may  be 
offered an appropriate medical therapy to facilitate stone passage during 
the observation period.
[Based on review of the data and panel opinion/Level 1A]
The  Panel  performed  a  meta-analysis  of  studies  in  which 
spontaneous  ureteral  stone  passage  was  assessed.  The  median 
probability of stone passage was 68% for stones ≤5 mm (n=224) and 
47%  for  those  >5  and  ≤10  mm  (n=104)  in  size  (details  previously 
discussed and provided in the appendixes). The Panel recognized that 
these studies had certain limitations including non standardization of the 
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stone size measurement methods and lack of analysis of stone position, 
stone-passage  history,  and  time  to  stone  passage  in  some.  A  meta-
analysis  of  MET was  also  performed  which  demonstrated  that  alpha 
nblockers  facilitate  stone  passage  and  that  the  positive  impact  of 
nifedipine is marginal. This analysis also indicates that alpha blockers 
are superior to nifedipine and, hence, may be the preferred agents for 
MET (details provided in the Appendixes). A similar benefit of MET 
was  demonstrated  in  a  recently  published meta-analytic  study.7.  The 
majority of stones pass spontaneously within four to six weeks.  This 
was demonstrated by Miller and Kane8, who reported that of stones ≤2 
mm, 2 to 4 mm and 4 to 6 mm in size, 95% of those which passed did so 
by 31, 40, and 39 days, respectively. In a choice between active stone 
removal and conservative treatment with MET, it is important to take 
into  account  all  individual  circumstances  that  may  affect  treatment 
decisions.  A  prerequisite  for  MET  is  that  the  patient  is  reasonably 
comfortable with that therapeutic approach and that there is no obvious 
advantage of immediate active stone removal.
Standard: Patients should be counseled on the attendant risks 
of  MET  including  associated  drug  side  effects  and  should  be 
informed that it is administered for an “off label” use.
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[Based on Panel consensus/Level IV]
Standard: Patients who elect for an attempt at spontaneous 
passage  or  MET]  should  have  well-controlled  pain,  no  clinical 
evidence of sepsis, and adequate renal functional reserve.
[Based on Panel consensus/Level IV]
Standard: Patients should be followed with periodic imaging 
studies to monitor stone position and to assess for hydronephrosis.
[Based on Panel consensus/Level IV]
Standard:  Stone  removal  is  indicated  in  the  presence  of 
persistent  obstruction,  failure  of  stone  progression,  or  in  the 
presence of increasing or unremitting colic.
[Based on Panel consensus/Level IV]
For Ureteral Stones >10 mm
Although patients with ureteral stones >10 mm could be observed 
or treated with MET, in most  cases such stones will  require surgical 
treatment.  No recommendation can be made for  spontaneous passage 
(with or without medical therapy) for patients with large stones.
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For Patients Requiring Stone Removal
Standard:  A  patient  must  be  informed  about  the  existing 
active treatment modalities, including the relative benefits and risks 
associated with each modality.
[Based on Panel consensus/Level IV]
Specifically, both SWL and URS should be discussed as initial 
treatment options for the majority of cases. 
Recommendation: For patients requiring stone removal, both 
SWL and URS are acceptable first-line treatments.
[Based  on  review  of  the  data  and  Panel  consensus/Level  1A-
IV.The meta-analysis demonstrated that URS yields significantly greater 
stone-free rates for the majority of stone stratifications.
Option: Laparoscopic or open surgical stone removal may be 
considered in rare cases where SWL, URS, and percutaneous URS 
fail or are unlikely to be successful.
[Based on Panel consensus/Level III]
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The 1997 AUA guideline stated that “Open surgery should not be 
the  first-line  treatment.”  The  invasiveness  and  morbidity  of  open 
surgery can be avoided. In very difficult  situations, however, such as 
with very large, impacted stones and/or multiple ureteral stones, or in 
cases  of  concurrent  conditions  requiring  surgery,  an  alternative 
procedure might be desired as primary or salvage therapy. Laparoscopic 
ureterolithotomy is a less  invasive alternative to open surgery in this 
setting.
Recommendations for the Nonindex Patient.
Standard: For septic patients with obstructing stones, urgent 
decompression  of  the  collecting  system with  either  percutaneous 
drainage or ureteral  stenting is indicated.  Definitive treatment of 
the stone should be delayed until sepsis is resolved.
[Based on Panel consensus/Level III]
Medical Expulsive Therapy53
There is growing evidence that MET, the administration of drugs 
to  facilitate  stone  passage,  can  be  efficacious.  Studies  have 
demonstrated  that  this  approach  may  facilitate  and  accelerate  the 
spontaneous  passage  of  ureteral  stones  as  well  as  stone  fragments 
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generated  with  SWL.34-38  Our  meta-analysis  demonstrated  the 
effectiveness  of  MET. Nine percent  (CI:  -7% to 25%) more  patients 
receiving nifedipine passed their stones than did controls in our meta-
analysis, a difference that was not statistically significant. In contrast, a 
statistically  significant  29% (CI:  20% to  37%)  more  patients  passed 
their stones with alpha blocker therapy than did control patients. These 
findings  indicate  that  alpha  blockers  facilitate  ureteral  stone  passage 
while nifedipine may provide a marginal benefit. Therefore, the Panel 
feels that alpha blockers are the preferred agents for MET at this time. 
Similar  findings have been reported by Hollingsworth and associates, 
who  recently  performed  a  meta-analysis  of  studies  involving  alpha 
blockers or nifedipine in patients with ureteral stones. The differences in 
methodology from our study have been previously mentioned. Patients 
given  either  one  of  these  agents  had  a  greater  likelihood  of  stone 
passage than those not receiving such therapy. The pooled-risk ratios 
and 95% CIs  for  alpha  blockers  and  calcium channel  blockers  were 
1.54.  The benefit  of  adding corticosteroids was reported to be small. 
Tamsulosin has been the most common alpha blocker utilized in these 
studies. However, one small study demonstrated tamsulosin, terazosin, 
and doxazosin  as  equally  effective  in this  setting.  These  studies  also 
demonstrated that MET reduces the stone passage time and limits pain. 
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The  beneficial  effects  of  these  drugs  are  likely  attributed  to  ureteral 
smooth muscle relaxation mediated through either inhibition of calcium 
channel  pumps or alpha-1 receptor blockade. Further prospective and 
randomized studies  are  warranted to determine  the patients  who best 
respond to MET. 
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MATERIALS & METHODS
All the patients who presented to the Urological Department in 
the  period  between  January  2007  to  January  2009  with  history 
suggestive of ureteric colic were evaluated for inclusion in the study 
• Informed consent obtained from all the patients.
• Patients were segregated into 3 groups.
• The investigator knew the patients in each of the groups before 
the start of the intervention, but the Patients didn’t. 
• All  details  regarding  patients  demographics,  Investigations, 
Outcome and complications were entered into the proforma.
Type of the study: Prospective Cohort study with control
Initial Evaluation
All the patients who presented with history suggestive of ureteric 
colic were evaluated with 
History &Physical Examination
Urinalysis &Urine culture Sensitivity 
Complete Blood Count
Renal Function Test
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USG KUB &X –ray KUB
Calculus size was measured based on X-ray KUB
X-ray KUB was taken initially, 28 days or after the calculus 
passed 
Inclusion criteria
 Renal colic due to radiologically proven distal ureteric calculus
Exclusion criteria : 
 Stone larger than 10 mm 
 Urosepsis 
 Additional calculus that might be the reason for the renal colic 
 Severe hydronephrosis 
 Known sensitivity to α blockers 
 Concomitant treatment with α blockers, β blockers, calcium 
 Antagonist, nitrates 
 Pregnancy 
 Inability to provide informed consent 
 Previous of surgery or endoscopic procedures in the urinary tract 
 History of spontaneous stone expulsion 
 Known ureteral stricture
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Patients were segregated into 3 groups
A Group Patients were given Placebo
B Group Patients were given Tamsulosin 0.4 mg/day
C Group Patients were given Alfuzosin 10 mg/day
Analgesics 100 mg SR tablets were given on demand
Duration of treatment – Until stone passage but not more than 
4wks
Primary endpoint of the study:
Calculus passage.
Discontinuation of treatment:
1. Intractable pain
2. Complications 
(i) Urosepsis
(ii) Drug related complication
Following Factors were analyzed:
Age
Sex
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Calculus passage rate -Stone size
Calculus passage time –Stone size
Patients requiring intervention 
Reason for intervention
Analgesics requirements
Statistical Analysis were done using SPSS
Chi-Square Test
Multiple range test -Turkey –HSD Test
Levene’s Test for equality of variance
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RESULTS & OBSERVATION
Total number of the patients 150. Patients were segregated into 3 
groups.50 patients were allotted in each groups
Age Stratification
Table 1 - Age Stratification
Age groups Group A Group B Group C
15-20 9(18%) 7(14%) 8(16%)
21-30 24(48%) 26(52%) 33(66%0
31-40 11(22%) 12(24%) 8(!6%)
41-50 6(12%) 5(10%) 1(2%)
 p = 0.44 
Mean  age  of  the  patients  in  Group  A  27.0  years  (range 
between18- 45 years), Group B 26.8 years (range between 18- 45 years) 
and in Group C 25.4 years (range between 18-41 years). Majority of the 
patients found to be in the age group of 21-30 years. Age distribution in 
all the 3 groups were found to be similar
Sex Stratification
Table 2 - Sex Stratification
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Sex Group A Group B Group C
Male 31(62%) 30(60%) 31(62%)
Female 19(38%) 20(40%) 19(38%)
p = 0. 97 
In all the 3 groups Male and Female patients were distributed in 
equal proportions.
Side Stratification
Table 3 - Side Stratification
Side Group A Group B Group C
Right 24(48%) 24(48%) 19(38%)
Left 26(52%) 26(52%) 31(62%0
p = 0.5
There was no side predominance in any of the groups.
Calculus Size Stratification 
Table 4 : Calculus Size Stratification
Calculus size Group A Group B Group C
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4mm 7 11 6
5mm 3 8 6
6mm 3 6 6
7mm 18 8 14
8mm 11 12 10
9mm 8 5 8
 p = 0.1382
Mean calculus size in Group A 6.98 mm (range between 4-9mm), 
in Group B 6.34mm (range between 4-9mm) and in Group C 6.78mm 
(range  between4-9mm).The  stone  size  was  found  to  be  equally 
distributed in all the groups.
Colicky pain stratification
Table 5 : Duration of Pain
Groups Mean Range
A 1.8 days 1-4 days
B 1.7 days 1-4 days
50
C 1.8days 1-5 days 
Patients had colicky pain for about 1.8 days before presentation 
duration ranged from (1-5 days).
Outcome stratification
Table 6 : Calculus Expulsion Rate
Groups Expulsion Failure Total
A 16(32%) 34(68%) 50(100%)
B 36(72%) 14(28%) 50(100%)
C 37(74%) 13(26%) 50(100%)
p=0.00001
Calculus expulsion rate in Group A, Group B and in Group C 
were  found  to  be  32%,72%,74%  respectively.  Difference  were 
statistically significant.
Table 7 : Expulsion of Calculus in relation to Stone Size
Calculus 
size
Group A Group B Group C
Expulsion Failure Expulsion Failure Expulsion Failure
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≤6mm 11 2 24 1 17 1
> 6mm 5 32 12 13 20 12
    p = 0.000001          p = 0.00016    p = 0.013
Only 4/56 (7.1%) cases had failures in ≤ 6mm groups, compared 
with  57/94  (60.6%)  in  >  6mm  groups.  This  difference  had  high 
statistical significance in all the groups.
Expulsion time stratification
Table 8 : Expulsion time in relation to treatments
Groups No of days of treatment
A 8.63 ± 3.24 days
B 7.75 ± 3.14 days 
C 8.57 ± 4.52 days 
p = 0.5961
There was no statistical significance in calculus expulsion time in 
all the 3 groups.
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Expulsion time stratification - calculus size ≤ 6 mm
Table 9 : Expulsion time of calculus size ≤ 6 mm
Groups No of days of treatment
A 7.36 ± 2.91
B 6.50 ± 2.50
C 5.53 ± 1.23
P =0.1155
There was no statistical significance in expulsion time of calculus 
≤ 6mm in all the 3 groups.
Expulsion time stratification - calculus size > 6 mm 
Table 10 : Expulsion time of calculus size > 6 mm
Groups No of days of treatment
A 11.40 ± 2.07
B 10.25 ±2.83
C 11.15 ± 4.70
    p =0.7844
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 There was no statistical significance in expulsion time of calculus 
>6mm in all the 3 groups.
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Intervention requirement (URS)
Table 11 : Intervention requirement
Groups No of cases
A 34 (68%)
B 14(28%)
C 13(26%)
      p= 0.00001
Intervention  requirement  (URS)  in  Group  A,  Group  B  and  in 
Group C were found to be 68%,28%,26% respectively. Difference were 
statistically significant.
Intervention requirement (URS) based on calculus size
Table 12 : Intervention requirement in relation to calculus size
Calculus size Group A Group B  Group C
≤ 6mm 2 (15.4%) 1(4%) 1(5.6%)
>6mm 32(86.5%) 13(52%) 12(37.5%)
 p value 0.00001 0.00016 0.0134
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Intervention  requirement  in  ≤  6mm  calculus  in  the  Group  A, 
Group  B  and  in  Group  C  were  15.4%,  4%,  5.6%  respectively. 
Intervention requirement in > 6mm calculus in the Group A, Group B 
and in Group C were 86.5%, 52%,37.5% respectively This difference 
had high statistical significance in all the groups.
Analgesic Requirements
Table 13 : Analgesic Requirements
Groups No. of doses of analgesic requirement
A 6.60 ± 1.82
B 3.86 ± 2.51
C 4.18 ± 3.02
p =0.03
The analgesic requirement was more in the placebo groups mean 
duration of more than 6 dose.
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DISCUSSION
150 Patients were included in the study. Patient were categorized 
into 3 groups. A Group Patients were given Placebo, B Group Patients 
were given Tamsulosin 0.4 mg/day and C Group Patients were given 
Alfuzosin  10  mg/day.  Analgesics  100  mg  SR tablets  were  given  on 
demand.Each group comprised  of  50 patients.Mean age group of  the 
patient  were in  Placebo (Group A) 27.0 years  (range between18-  45 
years), Tamsulosin (Group B) 26.8 years (range between 18- 45 years) 
and in Alfuzosin (Group C) 25.4 years (range between 18-41 years). 
Majority of the patients found to be in the age group of 21-30 years. Age 
distribution in all the 3 groups were found to be similar. Male :Female 
ratio  in  Placebo  (GroupA),  Tamsulosin  (Group  B)  and  in  Alfuzosin 
(Group C) found to be 1.6:1,1.5 :1,1.6:1 respectively. Right side :Left 
side ratio in Placebo (GroupA), Tamsulosin (Group B) and in Alfuzosin 
(Group C) found to be 1.08:1,1.08 :1,1.6:1 respectively. Mean calculus 
size were in Placebo (6.98± 1.6 mm).in Tamsulosin (6.34± 1.7mm) and 
in  Alfuzosin  (6.7± 1.5  mm).  The  size  of  calculus  were  found  to  be 
equally distributed in all 3 groups. Patients had colicky pain for about 
1.8 days before presentation, duration ranged in between (1-5 days)
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Table 14 : Comparison of various parameters 
Variable Group A Group B Group C Statistical 
significance
No of Pts 50 50 50
Age (years) 27±7.3 26.7± 7.4 25.4± 5.2 NS
SEX M:F 1.6:1 1.5:1 1.6:1 NS
Side R:L 1.08: 1 1.08:1 1.6:1 NS
Stone size 
mm
 6.98± 1.6 6.34± 1.7  6.7± 1.5 NS
Expulsion 
rate
32% 72% 74% 0.00001
Expulsion 
Time days
8.63 ± 3.24 7.75 ± 3.14 8.57 ± 4.52 NS
Ureteroscopy 68% 28% 26%  0.00001
Analgesic 
requirements 
(doses)
6.60 ± 1.82 3.86 ± 2.51 4.18 ± 3.02 0.03
In Placebo (Group A) Patients 16/50 (32%) of calculus found to 
be  expelled  and  34/50  (68%)  patients  required  interventions,  In 
Tamsulosin  (GroupB)  Patients  36/50  (62%)of  calculus  found  to  be 
expelled and 14/50 (28%) patients required interventions. In Alfuzosin 
(Group C) Patients 37/50 (74%) of calculus found to be expelled and 
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13/50 (26%) patients required interventions. Calculus expulsion rate in 
Placebo, Tamsulosin and in Alfuzosin were 32%, 72%,74% respectively
Multivariate analysis
Table 15 : Significance of variation among three groups
Variables Group A & Group B
Group A & 
Group C
Group B & 
Group C
Age NS NS NS
Stone size NS NS NS
Expulsion rate 0.00006 0.00003 NS
Expulsion time NS NS NS
Ureteroscopy 0.00002 0.00005 NS
There  was  a  statistically  significant  difference  in  calculus 
expulsion rate in between Placebo (Group A) & Tamsulosin (Group B) 
patients  and  in  between  Placebo  (Group  A)  & Alfuzosin  (Group C) 
patients. (This results are comparable with other studies) but there was 
no significant difference between Tamsulosin (Group B) & Alfuzosin 
(Group C) patients, so receptor sub selectivity is not a major concern. 
Only 4/56 (7.1%) cases had failures in ≤ 6mm groups, compared with 
57/94 (60.6%) in > 6mm groups.
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Table 16 : Distal Ureteral Stone Expulsion Rate (%)
Study With AlphaBlocker
Without Alpha
Blocker p Value
Cervenakov et al 80.4 62.8 N/A
Dellabella et al  100 70 0.001
Resim et al 86.6 73.3 0.196
De Sio et al 90 58.7 0.01
Yilmaz et al 79.31 (Tamsulosin)
78.57 (Terazosin)
75.86 (Doxazosin)
53.57
53.57
53.57
0.03
0.03
0.03
Porpiglia et al 85 43 < 0.001
Dellabella et al 97.1 64.3 <0.0001
This study 72 (Tamsulosin)
74 (Alfuzosin)
32 0.00001
This difference had high statistical significance in all the groups 
[(Placebo) p value = 0.000001, (Tamsulosin) p = 0.00016, (Alfuzosin) p 
= 0.013] Calculus expulsion time were found to be in Placebo Group 
A(8.63 ± 3.24 days), in Tamsulosin Group B (7.75 ± 3.14 days) and in 
Group  C  (8.57  ±  4.52  days).  There  was  no  statistically  significant 
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difference  found  in  between  the  groups.  There  was  no  statistical 
significance in expulsion time of calculus size of ≤ 6mm and in > 6 mm 
in all the 3 groups. Analgesics requirements was more in the placebo 
groups,  mean  duration  was  more  than  6  days.  61/150  of  patients 
required  ureteroscopy  &Lithotripsy  [Placebo  (Group  A)  34  (68%), 
Tamsulosin Group B 14(28%), Alfuzosin Group C 13(26%) ]. Reason 
for intervention were found to be intractable pain in 51 patients, Non 
Expulsion of calculus in 9 patients and due to dizziness (Adverse effect 
of Tamsulosuin) in 1 patient. Interventions were found to be more in the 
Placebo Group A patients [34 (68%)]. Discontinuation of the treatment 
due  to  side  effect  of  the  drug  is  almost  negligible.  No  patients 
complained  of  retrograde  ejaculation,  which  may  be  due  to  short 
duration of treatment and or a possible decrease or absence of coitus due 
to ureteric colic. 
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CONCLUSION
• Alpha  blockers  (Tamsulosin,  Alfuzosin)  improve  the  spontaneous 
expulsion rate of distal ureteric calculus.
• There  is  no  difference  in  distal  ureteric  calculus  expulsion  rate 
between Tamsulosin, and Alfuzosin.
• Alpha  blockers  reduce  the  analgesic  requirements  but  not  the 
calculus expulsion time. 
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Figure 1 : Right Distal Ureteric Calculus
Figure 2 : Left Distal Ureteric Calculus
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Figure 3 : Age Stratification
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Figure 5 : Side Distribution
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1 A1 22 M Lt 2 5 E 7 4 NO
2 B1 18 M Lt 1 6 E 5 2 NO
3 C1 23 M Lt 2 5 E 7 0 NO
4 A2 20 F Rt 2 7 F 10 4 URS Pain
5 B2 32 F Rt 3 8 E 5 3 NO
6 C2 24 M Lt 2 5 E 8 3 NO
7 A3 42 M Lt 1 4 E 5 2 NO
8 B3 23 F Lt 1 7 E 10 5 NO
9 C3 31 F Rt 2 7 F 12 2 URS Pain
10 A4 23 M Lt 3 4 E 7 2 NO
11 B4 21 M Rt 1 8 E 11 4 NO
12 C4 31 M Lt 1 9 E 18 6 NO
13 A5 21 F Lt 2 9 F 10 5 URS Pain
14 B5 35 F Lt 2 5 E 5 2 NO
15 C5 30 M Lt 1 7 E 10 3 NO
16 A6 41 M Rt 2 8 F 28 12 URS NEC
17 B6 21 F Rt 1 4 E 5 0 NO
18 C6 20 M Lt 3 7 F 20 7 URS Pain
19 A7 32 M Lt 2 8 F 15 6 URS Pain
20 B7 21 F Rt 3 9 F 20 5 URS Pain
21 C7 23 M Lt 2 7 E 9 6 NO
22 A8 21 F Lt 2 4 E 5 0 NO
23 B8 23 M Lt 1 7 E 9 6 NO
24 C8 21 F Lt 2 9 F 20 15 URS Pain
25 A9 20 M Rt 1 8 F 28 5 URS NEC
26 B9 30 M Rt 3 7 E 10 3 NO
27 C9 25 F Lt 1 9 F 10 5 URS Pain
28 A10 24 M Lt 2 5 E 12 3 NO
29 B10 18 M Lt 3 6 E 5 2 NO
30 C10 21 M Rt 1 8 E 11 4 NO
31 A11 20 F Rt 1 8 F 7 3 URS Pain
32 B11 27 M Lt 1 8 F 20 11 URS ADE
33 C11 28 F Lt 2 4 E 5 0 NO
34 A12 45 F Lt 1 7 F 11 7 URS Pain
35 B12 33 M Rt 2 5 E 3 1 NO
36 C12 30 F Lt 1 9 F 11 5 URS Pain
37 A13 33 M Rt 2 8 F 28 5 URS Pain
38 B13 28 F Rt 1 7 E 11 5 NO
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41 B14 28 M Lt 1 6 E 5 2 NO
42 C14 20 F Rt 2 4 E 7 3 NO
43 A15 31 M Rt 2 6 F 15 10 URS Pain
44 B15 22 M Rt 3 5 E 7 4 NO
45 C15 18 M Lt 1 6 E 5 2 NO
46 A16 23 M Lt 2 7 F 11 10 URS Pain
47 B16 20 F Rt 1 7 F 10 4 URS Pain
48 C16 32 F Rt 1 8 E 5 3 NO
49 A17 24 M Rt 2 7 F 12 3 URS Pain
50 B17 42 M Lt 1 4 E 5 2 NO
51 C17 23 F Rt 2 7 E 15 5 NO
52 A18 31 F Lt 1 7 F 20 2 URS Pain
53 B18 23 M Lt 2 4 E 7 2 NO
54 C18 21 M Lt 1 8 E 11 4 NO
55 A19 31 M Rt 2 9 F 25 6 URS Pain
56 B19 21 F Lt 1 9 F 10 5 URS Pain
57 C19 35 F Rt 2 5 E 5 2 NO
58 A20 30 M Lt 1 7 E 10 3 NO
59 B20 41 M Rt 3 8 F 28 5 URS NEC
60 C20 21 F Lt 1 4 E 5 0 NO
61 A21 20 M Lt 2 7 F 20 7 URS Pain
62 B21 32 M Rt 3 8 E 15 6 NO
63 C21 21 F Lt 3 9 F 20 5 URS Pain
64 A22 23 M Rt 3 7 F 9 6 URS Pain
65 B22 21 F Lt 1 4 E 5 0 NO
66 C22 23 M Rt 2 7 E 9 6 NO
67 A23 21 F Lt 1 9 F 20 5 URS Pain
68 B23 20 M Lt 4 8 F 28 5 URS NEC
69 C23 30 M Rt 1 7 E 10 3 NO
70 A24 25 F Rt 2 9 F 10 5 URS Pain
71 B24 24 M Lt 1 5 E 12 3 NO
72 C24 18 M Rt 3 6 E 5 2 NO
73 A25 21 M Lt 1 8 F 11 4 URS Pain
74 B25 20 F Rt 2 4 E 7 3 NO
75 C25 27 M Lt 1 8 F 20 11 URS Pain
76 A26 28 F Rt 2 4 E 5 0 NO
77 B26 45 F Lt 3 5 E 11 7 NO
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78 C26 33 M Rt 1 5 E 3 1 NO
79 A27 30 F Lt 2 9 F 11 5 URS Pain
80 B27 33 M Rt 1 8 F 28 5 URS NEC
81 C27 28 F Lt 2 7 E 15 5 NO
82 A28 33 M Rt 2 7 F 5 5 URS Pain
83 B28 31 M Lt 1 4 E 5 2 NO
84 C28 28 M Rt 2 6 E 5 2 NO
85 A29 20 F Lt 1` 6 F 7 3 URS Pain
86 B29 31 M Rt 2 6 F 15 10 URS Pain
87 C29 30 M Lt 1 6 E 7 3 NO
88 A30 41 M Lt 2 8 F 28 5 URS Pain
89 B30 21 F Rt 1 4 E 5 0 NO
90 C30 20 M Lt 2 7 F 20 7 URS Pain
91 A31 32 M Rt 1 8 F 15 6 URS Pain
92 B31 21 F Lt 2 9 F 20 5 URS Pain
93 C31 23 M Rt 1 7 E 9 6 NO
94 A32 21 F Lt 2 4 E 5 0 NO
95 B32 23 M Lt 1 7 E 9 6 NO
96 C32 21 F Rt 2 9 F 20 5 URS Pain
97 A33 20 M Lt 1 8 F 28 5 URS NEC
98 B33 30 M Rt 2 7 E 10 3 NO
99 C33 25 F Lt 1 9 F 10 5 URS Pain
10
0 A34 24 M Lt 2 6 E 12 3 NO
10
1 B34 18 M Rt 1 6 E 5 2 NO
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2 C34 21 M Rt 1 8 E 11 4 NO
10
3 A35 20 F Lt 1 4 E 7 3 NO
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1 C37 21 M Lt 1 8 E 11 4 NO
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2 A38 31 M Rt 1 9 F 25 6 URS Pain
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3 B38 21 F Lt 1 9 F 10 5 URS Pain
11
4 C38 35 F Lt 3 5 E 5 2 NO
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5 A39 30 M Rt 1 7 E 10 3 NO
11
6 B39 41 M Lt 1 8 F 28 5 URS NEC
11
7 C39 21 F Rt 4 4 E 5 0 NO
11
8 A40 20 M Lt 1 7 F 20 7 URS Pain
11
9 B40 32 M Rt 1 8 E 15 6 NO
12
0 C40 20 F Lt 1 5 E 7 3 NO
12
1 A41 21 M Rt 2 7 E 11 5 NO
12
2 B41 22 M Lt 2 6 E 7 3 NO
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3 C41 24 M Rt 2 8 E 5 10 NO
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4 A42 23 M Lt 3 7 F 15 10 URS Pain
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5 B42 31 M Rt 1 8 E 7 3 NO
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4 B45 40 F Lt 2 5 E 11 7 NO
13
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6 A46 25 F Rt 3 7 E 15 5 NO
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7 B46 23 F Lt 2 7 F 20 2 URS Pain
13
8 C46 33 M Lt 1 6 F 7 2 URS Pain
13
9 A47 22 M Rt 2 8 E 11 4 NO
14
0 B47 21 M Lt 1 8 E 11 4 NO
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1 C47 31 M Lt 5 9 E 25 6 NO
14
2 A48 21 F Rt 4 9 F 10 5 URS Pain
14
3 B48 35 F Rt 1 5 E 5 2 NO
14
4 C48 30 M Lt 2 7 E 10 3 NO
14
5 A49 41 M Rt 2 8 F 28 5 URS NEC
14
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14
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14
8 A50 32 M Rt 2 8 F 15 6 URS Pain
14
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15
0 C50 23 M Lt 2 7 E 9 6 NO
A- Placebo,   B-Tamsulosin   C-Alfuzosin    M-Male  F-Female  
Rt - Right,        Lt- left,   E- Expelled ,   F-Failure , INV-Intervention
81
NEC- Non Expulsion of calculus,  ADE – Adverse Effect
REV - Reasons for intervention
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PATIENT CONSENT FORM
Study Title : The Efficacy of Alpha-Blockers for Expulsion of Distal 
  Ureteral Stones 
Study Centre : Department of Urology
Patient’s Name :
Patient’s Age :
Identification No :
Patients may tick these Boxes [  ]
I confirm that I have understood the purpose of procedure for the above study. [  ]
I have the opportunity to ask the questions and all my questions and doubts [  ]
have been answered to my complete satisfaction.
I understand that my participation in the study is voluntary and that I am [  ]
free to withdraw at any time without giving any reason, without my legal
right being affected
I understand that sponsor of the clinical study, others working on the
sponsor’s behalf, the ethics committee and the regulatory authorities will
not need my permission to look at my health records both in respect of the [  ]
current study and any further research that may be conducted in relation
to it, even if I withdraw from study.
I agree to this access, however, I understand that my identity would not be [  ]
revealed. In any information released to third parties or published, unless as
required under the law.
I agree not to restrict the use of any data or results that arise from this study. [  ]
I agree to take part in the above study and to comply with the instructions
given during the study and to faithfully to cooperate with the study team, [  ]
and to immediately inform the study staff if I suffer from any deterioration
in my health or my well being or any unexpected or unusual symptoms.
I hereby give consent to participate in this study. [  ]
 
Signature / Thumb Impression .....................................................................................
of the patient:
Place : .........................................................................................
Patient’s name and address : .........................................................................................
Signature of the Investigator :.................................Place ......................Date ...............
Name of the Investigator : .............................................................................................
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PATIENT PROFORMA
Name:                                                Address:
Age:                 Sex:                I.P/O.P No:
                                                 I.D.No :
Complaints:
Physical Examination:
                                                                      
                                                                  B/P -              mm/Hg
Investigations:
Urinalysis:         Albumin:
                            Sugar:
                            Deposit:      Pus cells :
                                                  RBC:
Urine culture /sensitivity:
Total count:                                     P:       E:       L:       M:
Hb:                                   PCV:
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X –ray KUB:
Side:                                              Size of calculus:
IVU:
USG:
                                  RK                                             LK
Size:
PCS:
CMD:
Treatment Given:
TREATMENT OUTCOME:
Calculus  passed :            Yes:                             No:
If passed:             Size:
                              Time:
Analgesic requirement:
If not passed:        Intervention details :
Complications:
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